A Phase 1 interventional study of AZD4604 for inhalation via DPI and Placebo for AZD4604 for inhalation via DPI in Asthma, sponsored by AstraZeneca. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-20.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.
Among the 359 studies in Asthma by AstraZeneca, this one is the 146th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2022, is one of 46 in phase 1, and was the 275th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in China
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
AstraZeneca · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Argentina, Czechia and 4 more countries
Ages 4–11
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
359 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 52 · Phase 3 123 · Phase 4 23
First in 1996; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 175 across the 248 interventional studies, 500 across the 110 observational. Of the 330 that completed or were terminated, 129 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
13 of the studies in Asthma by AstraZeneca that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
| NCT07218172AstraZenecaCharacterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 359 studies in Asthma by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first in human clinical study. Part 1 of the clinical study will assess the safety and tolerability, as well as the single dose pharmacokinetics (PK), of inhaled AZD4604 in healthy volunteers (Part 1a, single ascending dose [SAD]). The single dose administration will be performed with dry powder inhaler (DPI) formulation of AZD4604. When at least 4 cohorts of the SAD part of the study have been completed, AZD4604 will be administered as a single intravenous (IV) or oral (PO) dose to 2 different cohorts of healthy volunteers (Part 1b). The main purpose is to compare the PK between IV, oral and inhaled administration to further characterize the PK properties of AZD4604 by the various administration routes. The results will be used to improve future study design and interpretation. In Part 2 (Multiple ascending dose [MAD]), AZD4604 will be administered at multiple doses (twice daily [BID], 7 days) to healthy volunteers. In Part 3, AZD4604 will be administered at multiple doses to patients with mild asthma at dose levels assessed in Part 2. The multiple-dose administration will be performed with DPI-formulated AZD4604.
Part 1a of the study will be a randomized, single-blind, placebo-controlled, SAD, sequential group design study. Seven inhaled dose levels of AZD4604 are planned to be investigated in cohorts of 8 healthy volunteers, with 6 healthy volunteers randomly assigned to inhaled AZD4604 and 2 healthy volunteers randomly assigned to inhaled placebo in each cohort.
Part 1a will comprise of:
In Part 1b, AZD4604 will be administered as a single IV or a PO dose to healthy volunteers in order to compare the PK between IV, PO and inhaled administration. Part 1b will be open-label and consist of 2 dose cohorts, IV and PO, with 6 healthy volunteers in each.
Part 1b will comprise of:
Part 2 of the study will be a randomized, single-blind, placebo-controlled, MAD, sequential group design. This part of the study will be conducted in up to 32 healthy volunteers.
Part 2 will comprise of:
Part 3 of the study will be a randomized, single-blind, placebo-controlled, multiple-dose, PK and pharmacodynamic (PD) study part, with daily non-residential visits during the Treatment Period. This part of the study will be conducted in at least 45 patients with mild asthma (16 patients in Cohorts 1 and 2 and at least 29 patients in the Proof of Mechanism [PoM] Cohort).
Part 3 will comprise of:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Study Parts:
Female subjects must have a negative pregnancy test at the Screening Visit and on admission to the Study Center or prior to randomization for Part 3 (Day -1 or Day 1 visit) and must not be lactating. Women of non-, must fulfill one of the following criteria:
Part 1a, Part 1b, and Part 2 Only:
Part 1a and Part 2 Only:
Part 3 Only:
Exclusion criteria:
All Study Parts:
Part 1a, Part 1b, and Part 2 Only:
Part 3 Only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 1 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 2 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 3 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 4 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 5 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 6 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 7 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
An additional cohort of healthy volunteers will receive a single inhaled dose of AZD4604 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Healthy volunteers will receive placebo administered with a DPI.
Drug: Placebo for AZD4604 for inhalation via DPI
Healthy volunteers will receive a single IV dose of AZD4604 administered as a 20 minute infusion.
Drug: AZD4604 for IV administration
Healthy volunteers will receive a single PO dose of AZD4604.
Drug: AZD4604 for oral administration
Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Healthy volunteers will receive placebo administered with a DPI.
Drug: Placebo for AZD4604 for inhalation via DPI
Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Patients will receive placebo administered with a DPI.
Drug: Placebo for AZD4604 for inhalation via DPI
Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.
Drug: AZD4604 for inhalation via DPI
Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI. Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7. Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10.
Healthy volunteers will receive a single IV dose of AZD4604 administered over 20 minutes. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
Healthy volunteers will receive a single PO dose of AZD4604. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
Part 1a: Number of healthy volunteers with adverse events (AEs)
Safety and tolerability of AZD4604 following inhaled administration of single ascending doses to healthy volunteers.
Time frame: From screening (SAEs only) up to Final assessment (Day 7)
Part 2: Number of healthy volunteers with AEs
Safety and tolerability of AZD4604 following inhaled administration of multiple ascending doses to healthy volunteers.
Time frame: From screening (SAEs only) up to Final assessment (Day 13)
Part 1b: Maximum observed plasma (peak) drug concentration (Cmax)
Cmax of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Time to reach peak or maximum observed concentration or response following drug administration (tmax)
tmax of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz)
λz of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t1/2λz)
t1/2λz of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Partial area under the plasma concentration time curve from time 0 to time 12 (AUC [0 - 12])
AUC (0 - 12) of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Partial area under the plasma concentration time curve from time 0 to time 24 (AUC [0 - 24])
AUC (0 - 24) of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)
AUClast of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)
AUClast of AZD4604 following PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Total body clearance of drug from plasma after intravascular administration (CL)
CL of AZD4604 following IV administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)
Vz/F of AZD4604 following PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Volume of distribution following intravascular administration (based on terminal phase) (Vz)
Vz of AZD4604 following IV administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Dose normalized AUClast, derived by AUClast divided by the dose administered (AUClast/D)
AUClast/D of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Area under plasma concentration-time curve from zero to infinity (AUCinf)
AUCinf of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Dose normalized AUCinf, derived by AUCinf divided by the dose administered (AUCinf/D)
AUCinf/D of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Dose normalized Cmax, derived by Cmax divided by the dose administered (Cmax/D)
Cmax/D of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 1b: Time of last observed (quantifiable) concentration (tlast)
tlast of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 3
Part 3: Number of patients with AEs
Safety and tolerability of AZD4604 following inhaled administration of multiple ascending doses to patients.
Time frame: From Screening (SAEs only) up to Final Assessment (Day 16)
Part1b: Number of healthy volunteers with AEs
Safety and tolerability of AZD4604 following IV and PO administration of a single dose to healthy volunteers.
Time frame: From screening (only SAEs) to follow-up end of treatment visit (6 ± 1 day post-dose)
Part 1a and Part 2: Cmax
Cmax of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)
Part 1a and Part 2: tmax
tmax of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)
Part 1a and Part 2: λz
λz of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7 (Part 1a) and on Day 7 (Part 2)
Part 1a and Part 2: t1/2λz
t1/2λz of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7 (Part 1a) and on Day 7 (Part 2)
Part1a: AUC (0 - 12)
AUC (0 - 12) of AZD4604 following inhaled administration of single ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7
Part 1a and Part 2: AUC (0 - 24)
AUC (0 - 24) of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7 (Part 1a) and on Day 7 (Part 2)
Part 1a and Part 2: AUClast
AUClast of AZD4604 following inhaled administration of single ascending doses and multiple ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)
Part 2: Area under plasma concentration-time curve in the dose interval (AUCτ)
AUCτ of AZD4604 following inhaled administration of multiple ascending doses to healthy volunteers.
Time frame: From Day 1 to Day 13
Part 1a: AUCinf
AUCinf of AZD4604 following administration of single ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7
Part1a: AUCinf/D
AUCinf/D of AZD4604 following inhaled administration of single ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7
Part 1a and Part 2: CL/F
CL/F of AZD4604 following inhaled administration of single and multiple ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7 (Part 1a) and on Day 7 (Part 2)
Part 1a and Part 2: Vz/F
Vz/F of AZD4604 following inhaled administration of single and multiple ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7 (Part 1a) and on Day 7 (Part 2)
Part 1a and Part 2: AUClast/D
AUClast/D of AZD4604 following inhaled administration of single and multiple ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)
Part 1a and Part 2: Cmax/D
Cmax/D of AZD4604 following inhaled administration of single and multiple ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)
Part 1a and Part 2: tlast
tlast of AZD4604 following inhaled administration of single and multiple ascending doses of AZD4604 to healthy volunteers.
Time frame: From Day 1 to Day 7 (Part 1a) and from Day 1 to Day 13 (Part 2)
Part 2: Dose normalized AUCτ, derived by AUCτ divided by the dose administered (AUCτ/D)
AUCτ/D of AZD4604 following inhaled administration of multiple ascending doses to healthy volunteers.
Time frame: From Day 1 to Day 13
Part 2: Accumulation ratio for AUCτ (Rac AUC)
Rac AUC of AZD4604 following inhaled administration of multiple ascending doses to healthy volunteers.
Time frame: On Day 7
Part 2: Accumulation ratio for Cmax (Rac Cmax)
Rac Cmax of AZD4604 following inhaled administration of multiple ascending doses to healthy volunteers.
Time frame: On Day 7
Part 1b: Renal clearance of drug from plasma (CLR)
CLR of AZD4604 following IV administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 2
Part 1b: Cumulative amount of unchanged drug excreted into urine from time t1 to time t2 (Ae [t1 - t2])
Ae (t1 - t2) of AZD4604 following IV administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 2
Part 1b: Cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 (fe [t1 - t2])
Fe (t1 - t2) of AZD4604 following IV administration of a single dose to healthy volunteers.
Time frame: From Day 1 to Day 2
Part 2: Cough severity self-assessment (Visual analog scale)
Effect of AZD4604 on cough severity in healthy will be evaluated volunteers when compared with placebo.
Time frame: Day-1 to Day 7 (Pre-dose) and Day 8 (Post -dose)
Part 3: Cmax
Cmax of AZD4604 following inhaled administration of multiple ascending doses to patients.
Time frame: From Days 1 to 16
Part 3: AUCτ
AUCτ of AZD4604 following inhaled administration of multiple ascending doses to patients.
Time frame: From Days 1 to 16
Part 3: AUC
AUC of AZD4604 following inhaled administration of multiple ascending doses to patients.
Time frame: From Days 1 to 16
Part 3: Cough severity self-assessment (Visual analog scale)
Effect of AZD4604 on cough severity in patients will be evaluated when compared with placebo.
Time frame: From Day -3 to -1, and Days 1 to 10
Part 3: Change from baseline in Fractional exhaled nitric oxide (FeNO) levels
Fractional exhaled nitric oxide (FeNO) levels will be assessed.
Time frame: From Day 1 to 10
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please re-refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Ran from Jul 2022 to primary completion in Jan 2023, 6 months.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 6 months is above that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Londamocitinib